Rs. 10,000 Crore for Biopharma SHAKTI: Can India Achieve 5% of the Global Market?
On February 3, 2026, the Union Budget announced the ambitious Biopharma SHAKTI scheme, allocating Rs. 10,000 crores over five years with the aim of transforming India's biopharmaceutical sector into a global leader. The target is explicitly framed: capture 5% of the estimated $700 billion global biopharma market. However, the claim demands scrutiny—not just the destination but the road to it.
Breaking New Ground, But How New Is It?
India’s biopharma ambitions are not novel, but their framing this year signals an escalation. The Biopharma SHAKTI scheme focuses on biologics and biosimilars, addressing high-value areas like monoclonal antibody therapies, recombinant insulin, and mRNA vaccines. The proposed establishment of 1,000 accredited clinical trial sites—a substantial improvement over current infrastructure—appears designed to position India as a competitive destination for cutting-edge R&D.
The scale of investment—Rs. 10,000 crores over five years—represents a financial commitment rivalling earlier initiatives like the *National Biopharma Mission (NBM)* launched in 2017. That scheme aimed to build a $100 billion biotech sector by 2025 but fell significantly short, achieving less than half its projected outcomes. Despite promising frameworks (World Bank co-funding, BIRAC implementation), structural bottlenecks—especially regulatory delays and uneven capacity—kept its progress muted. Whether Biopharma SHAKTI will truly break this entrenched cycle remains uncertain.
Institutional Machinery: Strong Vision but Slower Execution
The government’s machinery for biopharma development is extensive, weaving together multiple initiatives under DBT, CDSCO, and BIRAC leadership. Consider, for instance, the announcement of three new National Institutes of Pharmaceutical Education and Research (NIPERs), alongside the upgrade of seven existing institutes—a clear acknowledgment of India’s shortage of specialized human resources for biologics production and regulation. But the administrative precedent dampens enthusiasm: similar promises under previous schemes like PRIP (Promotion of Research and Innovation in Pharma-MedTech) have struggled with lagging execution.
On the regulatory side, the *Central Drugs Standard Control Organisation* (CDSCO) is set to receive additional technical personnel, presumably to streamline approval processes for biopharmaceuticals. While aligning with global timelines is flagged as a priority, India's approval framework remains burdened by opaque processes and inconsistent adherence to international standards. Section 12 of the Drugs and Cosmetics Act, which governs CDSCO’s powers, offers adequate flexibility, but systemic inefficiency bogs down efficacy. Could Biopharma SHAKTI unlock this long-stuck administrative door?
The Reality Check: Do the Numbers Add Up?
The headline ambition—capturing 5% of the global biopharma market—is marred by practical mismatches. India contributes less than 3% to global biologics production currently. Biosimilars manufacturing, while promising, faces hurdles such as patent litigation risks and challenges in meeting stringent export requirements for the EU and US markets, which together form over 50% of global demand.
The promise of 1,000 accredited clinical trial sites under Biopharma SHAKTI addresses some of these barriers. However, as per *India’s Clinical Trials Registry*, less than 400 such sites are presently active—and even fewer meet international accreditation. Scaling this capacity within the proposed five-year timeframe requires not only funding but state-level cooperation, which historically lacks consistency.
Investment figures are impressive but still fall short in context. Consider South Korea’s biopharma ascent: in 2018, Seoul allocated $2.8 billion toward biologics manufacturing and regulatory improvements under a five-year plan. The outcome? South Korea today captures close to 2% of the global biopharma market while ranking among the leaders in biosimilar exports. Comparatively, India’s Rs. 10,000 crore over five years appears generous but insufficient when competing in the high-stakes biologics domain.
Uncomfortably Silent Questions
What is conspicuously missing in the Biopharma SHAKTI announcement is a candid acknowledgment of India’s dependency on imported raw materials for biologics manufacturing. Despite schemes like the Bulk Drug Parks and PLI for pharmaceuticals, India imports nearly 70% of active biological ingredients (ABIs)—a glaring weakness incongruent with the ambition of global leadership.
Another uncomfortable silence surrounds the intersection of state implementation versus central policy frameworks. How uniform will the accreditation of clinical trial sites be across states with vastly different healthcare ecosystems? Tamil Nadu or Karnataka might readily meet targets; Bihar and Uttar Pradesh almost certainly will not.
Finally, what safeguards exist against regulatory capture under CDSCO’s enhanced capacity? The agency already faced criticism in 2021 over allegations of undue influence in granting accelerated vaccine approvals. Biopharma profitability often correlates with aggressive tactics. Will tightening regulatory efficiency inadvertently exacerbate risks of compromised oversight?
Lessons from South Korea’s Biologics Strategy
South Korea’s success in biosimilars offers cautionary insights. In 2018, its government made deliberate commitments to build a manufacturing ecosystem targeting only a few high-value biologics instead of stretching resources across multiple streams. Biocon—India’s leading producer of insulin analogs and biosimilars—has made strides under a similar focused model. Perhaps India’s policy planners overlooked the value of such specialization while spreading their interventions thinly across biologics, biosimilars, and advanced clinical ecosystems.
Another lesson lies in regulatory harmonization. South Korea’s FDA-equivalent agency adopted streamlined approval protocols modeled after USFDA procedures. India remains far behind, with approval timelines for biosimilars ranging from 16–24 months, double globally competitive averages. Biopharma SHAKTI identifies this gap but stops short of specifying concrete measures to address it effectively.
Practice Questions for UPSC
Prelims Practice Questions
- It allocates Rs. 10,000 crores over five years.
- It aims to capture 10% of the global biopharma market.
- It focuses on biologics and biosimilars.
Which of the above statements is/are correct?
- To reduce reliance on imported raw materials.
- To establish 1,000 accredited clinical trial sites.
- To enhance the manufacturing capabilities of existing biopharma products.
Which of the above statements is/are correct?
Frequently Asked Questions
What are the primary objectives of the Biopharma SHAKTI scheme?
The Biopharma SHAKTI scheme aims to transform India's biopharmaceutical sector with an investment of Rs. 10,000 crores over five years. Its explicit goal is to capture 5% of the $700 billion global biopharma market, focusing specifically on biologics and biosimilars such as monoclonal antibody therapies and mRNA vaccines.
How does the scale of investment in Biopharma SHAKTI compare to previous initiatives?
The Rs. 10,000 crores allocated for the Biopharma SHAKTI scheme is substantial, rivaling the earlier National Biopharma Mission (NBM) initiated in 2017. Although NBM aimed for a $100 billion biotech sector by 2025, it fell significantly short, illustrating a challenging landscape for ambitious biopharma goals.
What challenges does India face in meeting its biopharma production targets?
India currently contributes less than 3% to global biologics production and faces considerable challenges, including patent litigation risks and stringent export requirements, particularly from the EU and US markets. Moreover, the country relies heavily on imported raw materials, which undermines its goal of becoming a leader in the global biopharma market.
What role do clinical trial sites play in India's biopharma ambitions?
The establishment of 1,000 accredited clinical trial sites under the Biopharma SHAKTI scheme is intended to address current infrastructure shortcomings in India. Presently, less than 400 active sites exist, and scaling this up to meet both regulatory standards and international accreditation within the proposed timeline poses a significant challenge.
How does India's funding for biopharma initiatives compare to other countries?
While India has allocated Rs. 10,000 crores over five years for the Biopharma SHAKTI scheme, this figure pales in comparison to the $2.8 billion South Korea invested in biologics manufacturing in 2018. This disparity raises concerns about India's competitiveness in the global biopharma market, especially given South Korea's success in capturing 2% of the market.
About LearnPro Editorial Standards
LearnPro editorial content is researched and reviewed by subject matter experts with backgrounds in civil services preparation. Our articles draw from official government sources, NCERT textbooks, standard reference materials, and reputed publications including The Hindu, Indian Express, and PIB.
Content is regularly updated to reflect the latest syllabus changes, exam patterns, and current developments. For corrections or feedback, contact us at admin@learnpro.in.